Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. more
Time Frame | CTKB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.92% | -2.12% | 0.77% |
1-Month Return | -12.57% | -2.54% | 2.65% |
3-Month Return | 22.08% | -6.28% | 12.3% |
6-Month Return | 8.38% | -1.36% | 13.48% |
1-Year Return | -11.61% | 9.29% | 33.47% |
3-Year Return | -65.82% | 10.05% | 32.22% |
5-Year Return | -65.51% | 43.69% | 92.85% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 57.88M | 92.84M | 127.95M | 164.04M | 193.01M | [{"date":"2019-12-31","value":29.99,"profit":true},{"date":"2020-12-31","value":48.1,"profit":true},{"date":"2021-12-31","value":66.29,"profit":true},{"date":"2022-12-31","value":84.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 29.21M | 41.13M | 48.81M | 63.06M | 83.59M | [{"date":"2019-12-31","value":34.94,"profit":true},{"date":"2020-12-31","value":49.2,"profit":true},{"date":"2021-12-31","value":58.39,"profit":true},{"date":"2022-12-31","value":75.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 28.67M | 51.71M | 79.14M | 100.97M | 109.43M | [{"date":"2019-12-31","value":26.2,"profit":true},{"date":"2020-12-31","value":47.26,"profit":true},{"date":"2021-12-31","value":72.33,"profit":true},{"date":"2022-12-31","value":92.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 49.54% | 55.70% | 61.86% | 61.56% | 56.69% | [{"date":"2019-12-31","value":80.09,"profit":true},{"date":"2020-12-31","value":90.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.52,"profit":true},{"date":"2023-12-31","value":91.65,"profit":true}] |
Operating Expenses | 25.91M | 38.05M | 69.98M | 102.78M | 137.27M | [{"date":"2019-12-31","value":18.88,"profit":true},{"date":"2020-12-31","value":27.72,"profit":true},{"date":"2021-12-31","value":50.98,"profit":true},{"date":"2022-12-31","value":74.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 3.73M | 13.66M | 6.45M | (1.83M) | (27.84M) | [{"date":"2019-12-31","value":27.28,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":47.2,"profit":true},{"date":"2022-12-31","value":-13.37,"profit":false},{"date":"2023-12-31","value":-203.86,"profit":false}] |
Total Non-Operating Income/Expense | (19.31M) | 548.00K | (4.91M) | 5.11M | 17.36M | [{"date":"2019-12-31","value":-111.21,"profit":false},{"date":"2020-12-31","value":3.16,"profit":true},{"date":"2021-12-31","value":-28.28,"profit":false},{"date":"2022-12-31","value":29.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (16.29M) | 14.43M | 5.95M | 1.26M | (15.71M) | [{"date":"2019-12-31","value":-112.92,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":41.22,"profit":true},{"date":"2022-12-31","value":8.73,"profit":true},{"date":"2023-12-31","value":-108.86,"profit":false}] |
Income Taxes | 533.00K | (4.98M) | 1.50M | (1.22M) | (3.56M) | [{"date":"2019-12-31","value":35.42,"profit":true},{"date":"2020-12-31","value":-330.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-81.33,"profit":false},{"date":"2023-12-31","value":-236.61,"profit":false}] |
Income After Taxes | (16.83M) | 19.41M | 4.44M | 2.48M | (12.15M) | [{"date":"2019-12-31","value":-86.69,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22.89,"profit":true},{"date":"2022-12-31","value":12.8,"profit":true},{"date":"2023-12-31","value":-62.58,"profit":false}] |
Income From Continuous Operations | (16.83M) | 19.41M | 4.44M | 2.48M | (13.93M) | [{"date":"2019-12-31","value":-86.69,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22.89,"profit":true},{"date":"2022-12-31","value":12.8,"profit":true},{"date":"2023-12-31","value":-71.78,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.83M) | 19.41M | 4.42M | 2.58M | (12.15M) | [{"date":"2019-12-31","value":-86.69,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22.76,"profit":true},{"date":"2022-12-31","value":13.27,"profit":true},{"date":"2023-12-31","value":-62.58,"profit":false}] |
EPS (Diluted) | (0.03) | - | 0.12 | 0.14 | (0.09) | [{"date":"2019-12-31","value":-21.43,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":85.71,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-64.29,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CTKB | |
---|---|
Cash Ratio | 4.42 |
Current Ratio | 6.21 |
Quick Ratio | 5.47 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CTKB | |
---|---|
ROA (LTM) | -2.74% |
ROE (LTM) | -2.54% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CTKB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CTKB | |
---|---|
Trailing PE | NM |
Forward PE | 370.37 |
P/S (TTM) | 4.14 |
P/B | 2.16 |
Price/FCF | 67 |
EV/R | 2.83 |
EV/Ebitda | NM |
Cytek Biosciences Inc (CTKB) share price today is $6.47
Yes, Indians can buy shares of Cytek Biosciences Inc (CTKB) on Vested. To buy Cytek Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CTKB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cytek Biosciences Inc (CTKB) via the Vested app. You can start investing in Cytek Biosciences Inc (CTKB) with a minimum investment of $1.
You can invest in shares of Cytek Biosciences Inc (CTKB) via Vested in three simple steps:
The 52-week high price of Cytek Biosciences Inc (CTKB) is $9.87. The 52-week low price of Cytek Biosciences Inc (CTKB) is $4.66.
The price-to-earnings (P/E) ratio of Cytek Biosciences Inc (CTKB) is
The price-to-book (P/B) ratio of Cytek Biosciences Inc (CTKB) is 2.16
The dividend yield of Cytek Biosciences Inc (CTKB) is 0.00%
The market capitalization of Cytek Biosciences Inc (CTKB) is $861.75M
The stock symbol (or ticker) of Cytek Biosciences Inc is CTKB